Considering the set of results, we can hypothesize that P2Et treatment decreases lung inflammation by the modulation of the IL-33-ILC2-Eosino-IL-9 axis in early timepoints, but also trough the effect on innate immune populations. This evidence concerns the gene IL33 and inflammation.